埃博拉疫苗临床试验研究进展

被引：2

作者：

王雨潇 ^{[1
]}

李靖欣 ^{[2
]}

王杨 ^{[1
]}

朱文博 ^{[1
]}

朱凤才 ^{[2
]}

机构：

[1] 东南大学公共卫生学院流行病学与卫生统计学系

[2] 江苏省疾病预防控制中心疫苗临床评价所

来源：

传染病信息 | 2017年 / 30卷 / 02期

基金：

中央高校基本科研业务费专项资金资助;

关键词：

埃博拉病毒; 疫苗; 临床试验; 有效性; 安全性;

D O I：

暂无

中图分类号：

R392-33 [免疫学技术、设备及实验方法];

学科分类号：

100102 ;

摘要：

埃博拉病毒病以往被人们称作埃博拉病毒性出血热,目前尚无针对该病的特异性治疗措施与药物,疫苗成为最有可能预防控制病毒传播的手段。目前,多种埃博拉候选疫苗已经进入了临床试验,包括减毒水疱性口炎病毒载体埃博拉疫苗(rVSV-ZEBOV)、复制缺陷型黑猩猩3型腺病毒载体埃博拉疫苗(cAd3-EBO或ChAd3-EBO-Z)、复制缺陷型人5型腺病毒载体埃博拉疫苗(Ad5-EBOV)和人3型副流感病毒载体埃博拉疫苗(HPIV3)等。ChAd3-EBO-Z和Ad5-EBOV等在早期的临床试验中均表现出较好的安全性和免疫原性。rVSV-ZEBOV率先完成了Ⅲ期临床试验,已证实其对埃博拉病毒病的预防具有很高的保护效力,但是研究数据也提示了该疫苗可能存在的安全性问题。本文旨在回顾2014年以来埃博拉疫苗在临床试验研究方面的重大进展,讨论尚存的问题和挑战以及未来的发展方向。

引用

页码：82 / 85

页数：4

共 15 条

[1] 埃博拉病毒病疫苗研究进展 [J].

金宏丽 ;

王化磊 ;

郑学星 ;

杨松涛 ;

夏咸柱 .

传染病信息, 2015, 28 (02) :70-74

[2] 埃博拉病毒疫苗研究进展 [J].

杨利敏 ;

李晶 ;

高福 ;

刘文军 .

生物工程学报, 2015, (01) :1-23

[3]

基于重组腺病毒载体的烈性病原体疫苗研究.[D].吴诗坡.中国人民解放军军事医学科学院.2013, 11

[4]

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination; open-label; cluster-randomised trial (Ebola ?a Suffit!).[J].Ana Maria Henao-Restrepo;Anton Camacho;Ira M Longini;Conall H Watson;W John Edmunds;Matthias Egger;Miles W Carroll;Natalie E Dean;Ibrahima Diatta;Moussa Doumbia;Bertrand Draguez;Sophie Duraffour;Godwin Enwere;Rebecca Grais;Stephan Gunther;Pierre-Stéphane Gsell;Stefanie Hossmann;Sara Viksmoen Watle;Man

[5] Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial [J].

Li, Jing-Xin ;

Hou, Li-Hua ;

Meng, Fan-Yue ;

Wu, Shi-Po ;

Hu, Yue-Mei ;

Liang, Qi ;

Chu, Kai ;

Zhang, Zhe ;

Xu, Jun-Jie ;

Tang, Rong ;

Wang, Wen-Juan ;

Liu, Pei ;

Hu, Jia-Lei ;

Luo, Li ;

Jiang, Rong ;

Zhu, Feng-Cai ;

Chen, Wei .

LANCET GLOBAL HEALTH, 2017, 5 (03) :E324-E334

[6]

Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre; randomised; double-blind; placebo-controlled; phase 2 trial.[J].Feng-Cai Zhu;Alie H Wurie;Li-Hua Hou;Qi Liang;Yu-Hua Li;James B W Russell;Shi-Po Wu;Jing-Xin Li;Yue-Mei Hu;Qiang Guo;Wen-Bo Xu;Abdul R Wurie;Wen-Juan Wang;Zhe Zhang;Wen-Jiao Yin;Manal Ghazzawi;Xu Zhang;Lei Duan;Jun-Zhi Wang;Wei Chen.The Lancet.2017, 1006

[7] Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial [J].

Tapia, Milagritos D. ;

Sow, Samba O. ;

Lyke, Kirsten E. ;

Haidara, Fadima Cheick ;

Diallo, Fatoumata ;

Doumbia, Moussa ;

Traore, Awa ;

Coulibaly, Flanon ;

Kodio, Mamoudou ;

Onwuchekwa, Uma ;

Sztein, Marcelo B. ;

Wahid, Rezwanul ;

Campbell, James D. ;

Kieny, Marie-Paule ;

Moorthy, Vasee ;

Imoukhuede, Egeruan B. ;

Rampling, Tommy ;

Roman, Francois ;

De Ryck, Iris ;

Bellamy, Abbie R. ;

Dally, Len ;

Mbaya, Olivier Tshiani ;

Ploquin, Aurelie ;

Zhou, Yan ;

Stanley, Daphne A. ;

Bailer, Robert ;

Koup, Richard A. ;

Roederer, Mario ;

Ledgerwood, Julie ;

Hill, Adrian V. S. ;

Ballou, W. Ripley ;

Sullivan, Nancy ;

Graham, Barney ;

Levine, Myron M. .

LANCET INFECTIOUS DISEASES, 2016, 16 (01) :31-42

[8] The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial [J].

Huttner, Angela ;

Dayer, Julie-Anne ;

Yerly, Sabine ;

Combescure, Christophe ;

Auderset, Floriane ;

Desmeules, Jules ;

Eickmann, Markus ;

Finekh, Axel ;

Goncalves, Ana Rita ;

Hooper, Jay W. ;

Kaya, Gurkan ;

Krahling, Verena ;

Kwilas, Steve ;

Lemaitre, Barbara ;

Matthey, Alain ;

Silvera, Peter ;

Becker, Stephan ;

Fast, Patricia E. ;

Moorthy, Vasee ;

Kieny, Marie Paule ;

Kaiser, Laurent ;

Siegrist, Claire-Anne .

LANCET INFECTIOUS DISEASES, 2015, 15 (10) :1156-1166

[9] Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial [J].

Henao-Restrepo, Ana Maria ;

Longini, Ira M. ;

Egger, Matthias ;

Dean, Natalie E. ;

Edmunds, W. John ;

Camacho, Anton ;

Carroll, Miles W. ;

Doumbia, Moussa ;

Draguez, Bertrand ;

Duraffour, Sophie ;

Enwere, Godwin ;

Grais, Rebecca ;

Gunther, Stephan ;

Hossmann, Stefanie ;

Konde, Mandy Kader ;

Kone, Souleymane ;

Kuisma, Eeva ;

Levine, Myron M. ;

Mandal, Sema ;

Norheim, Gunnstein ;

Riveros, Ximena ;

Soumah, Aboubacar ;

Trelle, Sven ;

Vicari, Andrea S. ;

Watson, Conall H. ;

Keita, Sakoba ;

Kieny, Marie Paule ;

Rottingen, John-Arne .

LANCET, 2015, 386 (9996) :857-866

[10] Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial [J].

Zhu, Feng-Cai ;

Hou, Li-Hua ;

Li, Jing-Xin ;

Wu, Shi-Po ;

Liu, Pei ;

Zhang, Gui-Rong ;

Hu, Yue-Mei ;

Meng, Fan-Yue ;

Xu, Jun-Jie ;

Tang, Rong ;

Zhang, Jin-Long ;

Wang, Wen-Juan ;

Duan, Lei ;

Chu, Kai ;

Liang, Qi ;

Hu, Jia-Lei ;

Luo, Li ;

Zhu, Tao ;

Wang, Jun-Zhi ;

Chen, Wei .

LANCET, 2015, 385 (9984) :2272-2279

← 1 2 →